A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

This study is looking for adults aged 18 or older who have been diagnosed with chronic heart failure for at least three months. To join, your heart failure symptoms should fall into certain categories (NYHA Class II-IV), and your heart's main pumping chamber should be able to empty at least 40% of its blood with each beat (this is called your LVEF).

You'll also need to show signs of structural changes in your heart, such as a thicker heart wall or an enlarged upper heart chamber, which can be seen on heart scans. Additionally, a specific blood test called NT-proBNP needs to show elevated levels, which can be an indicator of heart strain.

If you are a woman who could become pregnant, you would need to use highly effective birth control throughout the study. All participants must be willing and able to sign a consent form, showing you understand what taking part involves.

If you decide to take part, you'll be given tablets to take once a day. These will either be the new combination of vicadrostat and empagliflozin, or a dummy pill (placebo) along with empagliflozin. You won't know which group you are in, and neither will your study doctor, as this helps make the results fairer.

You will have regular appointments with your doctors at a clinic. They will check your health, including your heart, and record any changes or side effects you might experience. Study staff may also call you occasionally to check in. You'll also be asked to complete questionnaires about how you are feeling and your overall well-being. The study doesn't have a set end date for each participant; you can continue as long as the treatment is helping you and you can tolerate it, and until the researchers have gathered enough information to understand if the treatment works for everyone involved.